US EditionGlaxoSmithKline Reports Strong Q2 Growth on Vaccine and Specialty Medicines Demand - Economy Watch
Summary by Economy Watch
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
GlaxoSmithKline Reports Strong Q2 Growth on Vaccine and Specialty Medicines Demand - Economy Watch
Please note that we are not authorised to provide any investment advice. The content on this page is for information purposes only. GlaxoSmithKline plc (GSK) announced strong second-quarter results on July 7, driven by robust sales of vaccines and specialty medicines. The UK-based pharmaceutical giant reported revenue of £12.6 billion ($15.4 billion), marking a 9% increase year-over-year, with net profit rising 11%. The company’s vaccine divisio…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
